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Abstract
Many common tests of model assumptions, including tests of covariate balance, placebo
outcomes, and parallel pre-intervention outcome trends, use a null hypothesis that
there is no violation. When researchers fail to reject this null hypothesis, they often
consider the assumption to hold. We argue that this approach is incorrect and often
misleading. First, these tests reverse the roles of Type I and Type II errors. Second, the
tests often have a high probability of failing to reject the null, even in the presence of an
assumption violation. Finally, even when power is adequate, these tests inappropriately
use sample size, rather than magnitude, to measure the importance of a violation. We
consider a reformulation of these tests in an equivalence/non-inferiority framework,
which controls Type I error. However, we show that this approach still may have low
power to rule out practically significant violations. We therefore suggest alternative
thresholds and sensitivity analyses. We apply our ideas to 3 papers that test critical
assumptions using conventional null hypothesis tests and consider how the conclusions
would change if our suggestions were applied.
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1 Introduction
In an American criminal court, defendants are presumed not guilty. The burden of proof
rests on the prosecutor to provide evidence that demonstrates guilt beyond a reasonable
doubt. If the evidence is insufficient, the jury declares the defendant “not guilty.” A “not
guilty” verdict does not imply that the defendant is innocent, only that there is insufficient
evidence of guilt to convict.
Statistical testing employs a similar approach. Researchers select a null hypothesis,
usually that there is no effect, and assume it to be true. They then assess evidence against it.
Substantial evidence against the null leads to rejection in favor of the alternative hypothesis.
In the face of only weak evidence against the null, insufficient data, or evidence in favor of
the null, we “fail to reject” the null. Failure to reject is as different from accepting the null
as “not guilty” is from “innocent.”
However, conventional tests of model assumptions often incorrectly interpret such a null
result as evidence that the assumption holds.1 Many models require similarity between
groups in certain features. For example, when conducting difference-in-difference analysis,
researchers use a parallel trends test to assess whether groups have different outcome trends
prior to the intervention. Likewise, when conducting a placebo test, they examine whether
a group that did not receive an intervention experienced a change in outcome or whether
a non-target outcome changed (i.e., “negative outcome controls” discussed in Sofer et al.
(2016)). Traditionally, these tests use a null hypothesis of “θ = 0” where θ measures the
size of a violation. If researchers fail to reject the null hypothesis, they often interpret this
as evidence that the assumption holds (i.e., “no violation”). Such tests are very common;
Table 1 presents some examples.
1By “model assumption”, we refer to testable conditions or prerequisites for analytical techniques Many
assumptions are untestable (e.g., no unmeasured confounding), but the work here pertains to conditions for
which we can obtain empirical evidence.
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Table 1: List of model assumption tests. (See Appendix A for search terms.)
Purpose Test Null hypothesis Alternatives Violation
parameter
on scale of
treatment
effect
Google
Scholar
results
(2013-17)
Test if data come from a nor-
mal distribution or two dis-
tributions are equal
Kolmogorov-Smirnov test Sample comes from reference distribu-
tion (1-sample) or two samples come
from same distribution (2-sample).
Robust regres-
sion techniques
No 27,500
Assess homoskedasticity Levene, Bartlett, White/Breusch-
Pagan tests
Errors are homoskedastic. Robust standard
errors
No 25,600
Test if data come from a nor-
mal distribution
Shapiro-Wilk, Anderson-Darling,
Jarque-Bera tests
Sample is drawn from a normal distri-
bution.
Robust regres-
sion techniques
No 24,100
Assess proportional hazards
assumption (Cox survival
analysis model)
Proportional hazards test There is no relationship between resid-
uals and time.
Sensitivity anal-
ysis
Yes 17,700
Assess goodness-of-fit in lo-
gistic regression
Hosmer-Lemeshow test Observed and expected proportions
are the same across variable values.
No 17,600
Assess if random effects are
appropriate
Durbin-Wu-Hausman test There is correlation between errors
and regressors.
Robust methods No 17,300
Test if time series is station-
ary
Dickey-Fuller (DF)/Augmented DF There is a unit root. No 13,600
Test if model is over-
identified (instrumental
variables)
Sargan-Hansen test Model is not over-identified. No 11,900
Test if there is an effect prior
to an intervention
Placebo test There is no effect. Yes 9,110
Check if distributions are the
same between treatment and
control groups
Balance tests There is no difference between treat-
ment and control groups.
Sensitivity anal-
ysis
No 7,390
Test if pre-intervention
trends are parallel
(difference-in-differences)
Parallel trends test Pre-intervention trends are parallel. Sensitivity anal-
ysis
Yes 3070
Test for manipulation of the
running variable (regression
discontinuity)
McCrary test There is no manipulation of the run-
ning variable.
Yes 531
Test if a linear model specifi-
cation is appropriate
Ramsey Regression Equation Speci-
fication Error Test (RESET) test
Non-linear model terms do not explain
the data better than only linear terms.
Yes 229
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However, in hypothesis testing, it is wrong to fail to reject the null and then conclude that
the null is true. Rather than putting the burden of proof on the investigator to demonstrate
that a modeling assumption holds, the tests in Table 1 assume that it holds and seek evidence
of a violation. If there is not enough information to assess whether there is a violation,
researchers will incorrectly conclude that none exists.
Previous work has found that these tests may have low power to rule out meaningful
violations. Freyaldenhoven et al. (2018) and Roth (2018) provide instances in which the
parallel trends test fails to detect important violations. Kahn-Lang and Lang (2018) discuss
this further, noting that failure to reject the null in parallel trends test does not indicate
evidence against the null. However, they do not discuss the spurious focus on “absence of
evidence” underlying these tests or contextualize them within study power. Likewise, when
presenting novel tests for which a large p-value suggests that an assumption holds, authors
often fail to discuss the power required to detect violations (e.g., McCrary (2008)).
In academic textbooks and statements, authors have discussed that p-value are not
meant to express the strength of evidence and are largely driven by sample sizes. For
example, in Mostly Harmless Econometrics, Angrist and Pischke (2008) state that tests of
over-identifying restrictions are “often of little value in applied work” for this reason. The
American Statistical Association released a statement stressing that “P-values do not mea-
sure the probability that the studied hypothesis is true”, “[do] not measure the size of an
effect or the importance of a result” and should not be the sole basis of scientific or pol-
icy decisions. (?) Despite this, conventional hypothesis tests and p-value-driven decisions
about modeling assumptions remain ubiquitous. To our knowledge, our paper is the first
to 1) discuss why these tests often have low power; 2) explain that p-values do not provide
useful signals for whether model assumptions hold; and 3) propose alternative procedures,
including equivalence testing and sensitivity analyses.
To illustrate the problem of low power, consider the probabilities in Table 2. For a test
of an effect of scientific interest, we begin with the null hypothesis that there is no effect
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and reject this when p < α. If this test has 75% power for effects of size θ = θ∗ and we use
α = 0.05, there is a 5% chance of finding an effect if there is none, and at least a 75% chance
of finding an effect at least as large as θ∗. Here, Type I error is controlled strictly at 5%.
We prioritize protecting against falsely declaring that scientifically interesting results exist.
Similarly, in the usual test of a modeling assumption, we begin with the analogous null
hypothesis that there is no violation and reject this when p < α. For the same power and α,
we have a 5% chance of incorrectly concluding that there is a violation when there is none,
and a 25% chance of failing to detect a violation at least as large as θ∗. We believe the
important type of error is missing a violation of at least θ∗, but we have only controlled that
probability at 25%. By contrast, we have tightly controlled at 5% the probability of falsely
detecting a modeling violation that does not exist. We argue that the roles of these two
error types (and thus the null hypothesis) should be reversed. However, following that line
of reasoning, we quickly see how conventional tests have low power to rule out violations of
assumptions. To control the probability of concluding no violation at 5%, the original test
would have needed 95% power, well above the conventional standard of 70− 80%.
Table 2: Probabilities of hypothesis test results (α = 5%, power= 75%)
Under H0: There is no
effect.
Under HA: There is an
effect.
Probability of detecting an
effect
5% (false positive) 75% (true positive)
Probability of a null result 95% (true negative) 25% (false negative)
Moreover, researchers rarely report power for their tests of scientific interest, let alone for
tests of modeling assumptions. Therefore, when model assumption tests that use the null
hypothesis of “no violation” are presented, the reader has no way to gauge the probability
of failing to detect assumption violations. The p-value alone does not communicate this
characteristic of the test, leaving the reader little sense of the confidence she should have in
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the modeling assumptions.
Furthermore, even when power is adequate, these tests are oriented toward statistical,
rather than practical, significance. We argue that researchers should be more interested in
the magnitude of violations. Violations that are large enough to impact the conclusions
of the modeling approach matter. However, traditional tests do not focus on ruling out
meaningful or important violations. Rather, they detect statistically significant violations.
As we see in Table 2, in many cases, this may mean that we fail to detect important violations.
Conversely, with very high power, we may find statistically significant violations that are
too small to affect our results.
In this paper, we consider alternative hypothesis tests developed to show equivalence
or non-inferiority of two treatments. We explain how to formulate tests of assumptions as
equivalence/non-inferiority tests and then consider challenges of this approach, namely low
power and the difficulty of choosing an equivalence/non-inferiority margin. We propose alter-
native approaches to assess modeling assumptions. We illustrate these with three examples
from the literature, showing that critical assumptions may not hold.
2 Non-inferiority framework
Consider a standard hypothesis test of a model assumption, measured by a parameter θ.
A few examples of θ include:
• Parallel trends test: In a parallel trends test for difference-in-differences (DID), θ is
the difference in slope between treatment and control groups prior to the intervention.
• Placebo test: In a placebo test, θ is the change in outcome in the group that should
be unaffected by the intervention.
If researchers perform a conventional test, they have a null hypothesis of no violation:
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H0 : θ = 0
HA : θ 6= 0
The challenge of demonstrating similarity is not unique to tests of model assumptions. In
biomedical research, researchers may wish to demonstrate that two treatments are equivalent.
A large body of literature, mainly in clinical trials methods, re-formulates the null hypothesis
to hold that the two treatments differ by at least some clinically meaningful amount (Hahn
(2012)). Then the burden of proof is on the researcher to demonstrate that they do not.
When there is insufficient evidence, researchers do not conclude that the treatments are
equivalent.
This suggests a fix to the problem identified above (also identified by Hartman and
Hidalgo (n.d.)). We can use equivalence (or non-inferiority) tests to put the burden of
proof on the researcher to demonstrate that modeling assumptions hold. Researchers specify
a threshold, δ, for a meaningfully large violation of an assumption. They then test the
parameter θ:
H0 : θ ≥ |δ|
HA : θ < |δ|
Adopting language from clinical trials methods, we call this two-sided test one of “equiva-
lence”. Omitting the absolute values yields a one-sided test, which we call a “non-inferiority”
test.
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2.1 Equivalence/non-inferiority margins and intervals
Traditionally, researchers choose an equivalence/non-inferiority threshold based on clini-
cal knowledge. One can also examine a range of thresholds, as displayed in Figure 1. Figure
1 plots p-values (on the y-axis) for non-inferiority tests at different possible margins (on the
x-axis). From this plot, we can find the value of δ at which our rate of falsely declaring no
violation (for violations at least that big) is controlled at 5%. There is always some violation
size for which the test has 95% power. The value of δ at which the p-value dips below 0.05,
or approximately δ = 0.14 in Figure 1, is this threshold. If violations smaller than θ = 0.14
are practically important, we should not feel confident that this test can rule these out.
Figure 1: Non-inferiority plot. The x-axis indicates the non-inferiority margin, and the y-
axis the p-value. The dotted horizontal line indicates p = 0.05. The solid line corresponds to
the p-value associated with a test that the effect is less than the corresponding equivalence
margin.
The δ in Figure 1 where the p-value crosses 0.05 (that is, the smallest effect that can
be ruled out with a 5% error rate) is equivalent to the upper bound on the one-sided 95%
confidence interval for θ. Thus uncertainty bounds on θ are a useful way to understand the
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evidence against large violations.
To understand this relationship between non-inferiority testing and the confidence in-
terval, recall the link between confidence intervals and hypothesis tests: we reject the null
hypothesis of “no effect” at the α level if 0 does not lie in the 1 − α confidence interval.
The same relationship holds for other null hypotheses. In fact, for many tests, confidence
intervals are explicitly made by inverting the test statistic. To do this, researchers create a
confidence interval with coverage 1−α by examining a range of values for the null hypothesis,
calculating a test statistic, and including the value in the confidence interval only if p > α
for the test.
However, when reporting both p-values and confidence intervals for tests of assumptions,
researchers rarely interpret the results in an equivalence/non-inferiority framework. Instead,
the usual language might be, “We find no evidence of an effect (p = 0.6, 95% CI: -1.4 to
2.6).” Confidence intervals may not be discussed in part because their proper interpretation,
involving infinite repeated experiments under the null, is cumbersome. However, it would be
useful to state, “We can rule out effects less than -1.4 and greater than 2.6 at the α = 0.05
level,” and interpret the magnitude of these effects in the context of the problem. Researchers
might also provide confidence bounds for different values of α and provide a one-sided interval
for a one-sided test, as applicable.
3 Practical challenges of equivalence/non-inferiority tests
The equivalence/non-inferiority formulation of assumption tests allows accurate charac-
terization of uncertainty and selection of a practically significant violation threshold. How-
ever, this approach requires a reasonable equivalence/non-inferiority threshold and accept-
able power, both of which are challenging.
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3.1 Tests with a parameter measured on the scale of the treatment
effect
We first consider assumption tests that examine a violation parameter that is on the scale
of the parameter of scientific interest, which we call the “treatment effect.” For example,
in the parallel trends test, the violation parameter is the differential change in outcomes
between two groups prior to the intervention, just as the treatment effect is a differential
change in outcomes between the two groups over the whole period (see Table 1 for additional
tests). In these cases, it is sensible to choose a non-inferiority threshold with reference to
the parameter of interest. We can understand relevant thresholds and the power of a non-
inferiority test to rule out violations relative to power of the main study. However, as we
discuss next, in many cases, power to rule out relevant effects will often be quite low.
3.1.1 Heuristic for non-inferiority power
In general, if a one-sided test has probability 1 − β of detecting θ ≥ θ∗ (given such an
effect exists), then the non-inferiority formulation will have probability approximately 1− β
of ruling out violations θ ≥ θ∗ (given no violation exists).
Consider a stylized example: suppose we want to study the effect of an intervention
on a treated group. We compare the treated group’s post-treatment mean θ to an a
priori -specified reference point. For simplicity, we assume the reference value is 0 here.
(In Appendix B, we generalize this to other reference values.) We specify a one-sided
test with H0 : θ ≤ 0 versus the alternative HA : θ > 0. With data from N subjects
Xi, . . . , XN
iid∼ N(θ, σ2), we write a test statistic ZN = X¯σ/√N and reject the null when the
test statistic exceeds a critical value. Using the distribution of the test statistic under the
null, the critical value should be Φ−1(1−α) to control type I error at α. Then, by definition,
the power 1− β is the probability that the test statistic exceeds the critical value under the
alternative,
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1− β = Pr (ZN > Φ−1(1− α)|θ > 0) ,
which, for every value of β, will be true for some value of θ = θ∗.
We subtract θ
σ/
√
N
from each side,
1− β = Pr
(
ZN − θ
σ/
√
N
> Φ−1(1− α)− θ
σ/
√
N
)
.
Then, because X¯ ∼ N
(
θ, σ
2
N
)
, we know ZN − θσ/√N = X¯−θσ/√N ∼ N(0, 1). We can rewrite
our expression as
1− β = 1− Φ
(
Φ−1(1− α)− θ
σ/
√
N
)
.
Using 1− Φ(x) = Φ(−x), and −Φ−1(α) = Φ−1(1− α) for α ∈ [0, 1], we rearrange as
1− β = Φ
(
Φ−1(α) +
θ
σ/
√
N
)
; .
We solve for θ∗, which is the smallest treatment effect the test has power 1−β to detect,
θ∗ = σ/
√
N
(
Φ−1(1− β)− Φ−1(α)) .
That is, if θ = θ∗, we will have power 1− β to reject the null that θ ≤ 0.
Now suppose we wish to verify our assumption that 0 is a good reference value, and do
so by examining the mean of a comparable untreated group. Our task is to establish that
the untreated group’s mean does not exceed 0. Following the reasoning above, we formulate
a non-inferiority test with a bound based on the θ∗ from the main study. That is, we wish
to test whether we can rule out differences (relative to the reference of 0) in the control
group’s mean that are at least as big as the treatment effect we are powered to detect. The
hypotheses are therefore H0 : θ ≥ θ∗ versus HA : θ < θ∗. We assume the untreated group’s
data are X1, . . . , XN
iid∼ N(θ, σ2) and write a test statistic ZN = X¯−θ∗σ/√N . We reject violations
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when the test statistic is smaller than a critical value. As before, we determine the critical
value by assuming that the null is true and controlling the Type I error rate at α, which
yields a critical value of Φ−1(α).
We are interested in the power of the test when the assumption is exactly met, that is,
when θ = 0. Again by definition,
P
(
ZN ≤ Φ−1(α)
∣∣∣θ = 0) = P ( X¯
σ/
√
N
≤ Φ−1(α) + θ
∗
σ/
√
N
∣∣∣∣∣θ = 0
)
.
Because θ = 0, X¯
σ/
√
N
∼ N(0, 1). Plugging in the standard normal cumulative distribution
function and our expression for θ∗, we obtain
Φ
(
Φ−1(α) +
(
Φ−1(1− β)− Φ−1(α))) = 1− β .
Therefore, when the assumption is met, our power to rule out a violation as big as the
treatment effect for which our main analysis is powered is the same as the power of the
main study. Put another way, if the main study is just powered for all treatment effects of
practical significance, the test of assumptions will be just powered to detect violations of
that magnitude.
This same relationship applies to t-tests and Wald tests of regression coefficients, as well
as two-sample tests (see Appendix B for further detail). For a two-sided test of the treatment
effect, the non-inferiority test has slightly higher power than the original test, while a two-
sided null hypothesis for the non-inferiority test has lower power. (See Appendix C for more
discussion of these conditions.) However, the general benchmark provides a useful guideline.
3.1.2 Implications
Although the heuristic may appear to suggest that a well-powered study is well-powered
to examine assumptions, in many cases, the power will still be insufficient. First, tests
of model assumptions often guide whether an analysis should be performed. Therefore,
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researchers may need to pass both the model assumption test and the main treatment effect
test to report a positive result. Even if researchers were only interested in ruling out violations
of the same magnitude as the treatment effect the main study is powered to detect, there is
a lower probability of passing both the model assumption test and the treatment effect test.
For example, if both have 75% power and the tests are fairly independent, then the study’s
power is only about 56%. This problem is exacerbated by several common factors, detailed
below.
When the power of the initial study is low: Low study power is a challenge in
many fields (Rokicki et al., 2018; Ioannidis et al., 2017). If the power of the main study is
low, the power of tests of modeling assumptions to rule out quantities of interest will also
be low. Suppose a test has 50% power to detect a treatment effect of size θ0 for the primary
quantity of interest. The researchers want to run a placebo test to assess whether a change
existed in a population that should not have been affected by the treatment. If the placebo
sample is the same size as the main study sample, they have only 50% power to rule out a
placebo effect of the same size as the treatment.
When tests of assumptions have small sample sizes: Tests of modeling assump-
tions often have lower power than the main study. For instance, researchers may perform
a placebo test on a portion of the sample. Likewise, to perform a parallel trends test, re-
searchers must exclude data from after the start of the intervention, also reducing the sample
size.
When important violations may be small: A non-inferiority test will have much
lower power to rule out a violation smaller than the treatment effect of interest. For example,
in Figure 2, we display the power to rule out violations smaller than the treatment effect.
Suppose the main study has 75% power to detect an effect of θ = δ. As the top line shows,
there is 75% power to rule out violations greater than or equal to δ if there is truly no effect
(θ = 0). However, if were are interested in smaller violations we have much less power. For
example, we have only 31% power to rule out a violation ≥ 0.5δ when θ = 0. In the context
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of the parallel trends test, this would suggest we have low power to rule out violations that
might account for half of our treatment effect, even if the study is well powered.
When the true violation is not zero: Suppose our main study has 75% power to
detect an effect of size δ. We have 75% power to rule out this violation if it is truly 0, the
peak of the top line in Figure 2. However, as the true violation increases, power decreases,
corresponding to the different lines in Figure 2. For example, if there is a true violation
of θ = 0.5δ, we have only 25% power to rule out a violation of size δ. Even if the true
violation size is not practically significant, it will nevertheless reduce power to rule out large
violations.
θ = 0
θ = 0.25δ
θ = 0.5δ
θ = 0.75δ
θ = δ
0.00
0.25
0.50
0.75
1.00
0.25 0.50 0.75 1.00
p (proportion of main treatment effect, δ)
Po
w
e
r 
to
 re
jec
t H
0:
 θ
≥
pδ
θ = 0
θ = ± 0.25δ
θ = ± 0.5δ
θ = ± 0.75δ
θ = ± δ0.00
0.25
0.50
0.75
1.00
0.25 0.50 0.75 1.00
p (proportion of main treatment effect, |δ|)
Po
w
e
r 
to
 re
jec
t H
0:
 θ
≥
p|δ
|
Figure 2: The left panel refers to a one-sided test and the right panel to a two-sided test.
The x-axis indicates the value of p in the null hypotheses, θ ≥ pδ and θ ≥ p|δ| respectively.
The y-axis indicates the power to reject this null, with each line indicating a different true
effect size. Maximum power is achieved when θ = 0, and power decreases as θ, the size
of the violation, increases. The solid lines show power to reject in cases in which the null
hypothesis is not true; the dotted line refers to the case when θ = δ, thus falling under the
null hypothesis.
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3.2 Tests without a parameter measured on the scale of the treat-
ment effect
For tests that do not have a violation parameter measured on the same scale as the
treatment effect, it is difficult to set an equivalence/non-inferiority threshold. In balance
tests, for example, researchers examine if there were differences in treatment and control
group covariates prior to an intervention. However, imbalance only affects results to the
extent that a covariate is correlated with the outcome, a relationship that renders threshold-
setting difficult. For many tests of normality, this issue is exacerbated as the test statistic is
not measured in units that are easy to connect to the larger study question. These challenges
make it difficult to switch to equivalence/non-inferiority tests.
Likewise, it is more difficult to assess the power equivalence/non-inferiority tests in the
context of the main study. Some tests have low power to reject the null, such the as
Kolmogorov-Smirnov test for normality. Other tests are more sensitive to small deviations
of assumptions, like Bartlett test’s for equality of variances. It is reasonable to expect that
some tests would have low power in an equivalence/non-inferiority context.
4 Recommendations
Given the challenges outlined above, what should conscientious researchers do to present
evidence that crucial modeling assumptions hold? Below, we offer a few recommendations.
4.1 Avoid tests of modeling assumptions.
In some cases, researchers can avoid tests of model assumptions altogether. They might
use information about study design to assess assumptions. For example, it may be reasonable
to assume equal variances between groups in randomized controlled trials, but less reasonable
in an observational study.
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In addition, researchers might substitute tests that require fewer or less stringent assump-
tions (see Table 1 for alternatives). While these robust tests often have lower power for the
treatment effect, the decrease in power may be less than needed to verify the assumptions
of a more powerful test. This approach is already common for some analyses. For example,
the normality and homoskedasticity assumptions of linear regression are easily circumvented
by more flexible regression models.
4.2 Take an equivalence/non-inferiority approach
At a minimum, researchers should avoid tests in which failure to reject the null is taken
as evidence that an assumption holds. Statistical tests never prove the null hypothesis.
Many tests of model assumptions are likely to suggest “no violation” when statistically
and practically significant violations exist. This problem exists in well-powered studies, as
described in Table 2, and is even more acute in studies with low power. Where feasible,
researchers should use an equivalence/non-inferiority approach, which allows researchers to
specify a practically significant violation magnitude and accurately quantify uncertainty
around violations of model assumptions.
In particular, a non-inferiority approach may be useful when conducting placebo tests.
In placebo tests, researchers examine whether an effect exists in an unrelated population or
non-target outcome. For example, a study examining the effect of racial discrimination may
test whether an effect holds among people of different races from the same neighborhood as
the population of interest. In this context, researchers can test whether they can rule out
effects the same size as the main treatment effect. While these tests may have low power,
they may nevertheless contextualize evidence about the treatment effect. In addition, if
authors have very large sample sizes and thus very high power, non-inferiority tests may be
feasible.
Furthermore, when examining assumptions, researchers may be satisfied with a lower
burden of proof for ruling out violations than in the main test of effects of scientific interest.
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However, this trade-off must be made explicitly. In a non-inferiority framework, we control
the probability of failing to detect violations ≥ δ with the α threshold. We argue that this is
the more important type of error (compared to declaring a violation where none exists), and
therefore the one that deserves attention and reporting. However, researchers may be willing
to openly and explicitly accept a higher probability of failing to detect violations by raising
the threshold α from its traditional value of 0.05. For example, setting α = 0.25 would be
roughly equivalent to common practice of assuming no violation when p > 0.05 and power
of 75%. Alternatively, Bayesian regression methods can allow researchers to make direct
probability statements about the probability of violations exceeding a specified size. This
approach does not obviate the need to define equivalence/non-inferiority thresholds, but it
ensures that researchers accurately present the error rates for their tests of assumptions.
4.3 Perform sensitivity analyses
Rather than focusing on testing model assumptions, researchers can explicitly consider
model assumptions through the lens of the research question: “If this assumption is violated,
how would it affect the main conclusion?” For example, suppose a researcher uses a simple
regression model for a difference-in-differences analysis. In this setup, there are two groups
indexed by j, a treated (j = 1) and a comparison group (j = 2). Let i index time and
suppose that an intervention begins after time T for the treated group. A simple linear
regression model takes the form:
yij = β0 +
∑
k>T
β1kI(tij = k ∩ j = 1) + β2tij + θj + ij, (1)
where yij is the outcome for group j at time i, θj is a group fixed effect, and β2 is a
(linear) time trend.2 The treatment effects of interest are the β1k parameters that represent
differential post-period deviations in the treated group relative to the control.
2Linear time trends are not required and will be unrealistic in many scenarios, but we use this simplifi-
cation to develop ideas here.
16
This first model implicitly assumes that the difference in pre-period trends is 0 and that
this common linear trend in untreated outcomes applies to both groups over the whole study
period. To justify this assumption, researchers often specify a more general model that
allows different pre-intervention trends, such as
yij = β0 +
∑
k>T
β1kI(tij = k ∩ j = 1) + β2tij + β3tijI(j = 1) + θj + ij , (2)
and then test whether the differential time slope β3 = 0. Typically this will be fit to the
pre-period data only and will therefore omit the post-intervention parameters. If p > 0.05
for this test, researchers then conclude that trends are parallel and report results from the
constrained model in Eq. (1). The same procedure might follow from an equivalence/non-
inferiority test of β3. That is, having concluded that meaningfully large values of β3 can be
ruled out, a researcher may feel justified reporting results from the constrained model.
However, an non-hypothesis test alternative is to report the results of second more flexible
model. Under traditional assumptions, the joint distribution of the parameters in the model
in Eq. (2) is available. From this, a researcher can calculate a confidence interval for the
treatment effects that incorporates both the magnitude and uncertainty of the violation
represented by β3.
This approach does not formally compare the size of the treatment effect with a violation
to that without a violation, but does incorporate the uncertainty of the violation parameter.
Similar approaches have been applied to estimate the impact of unobserved confounders
and missing data (?Imai et al., 2010). Many tests could be similarly amenable to similar
sensitivity analysis (see Table 1).
5 Examples
We explore our results with some examples from academic papers. We selected articles
from reputable journals with clearly presented results to demonstrate our ideas and do not
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intend to impugn these authors or their conclusions.
5.1 Food stamps and health and economic outcomes
A 2016 paper in the American Economic Review assessed the impact of the introduction
of the Food Stamp program on adult health and economic outcomes. (Hoynes et al., 2016)
As a placebo test, they examined the highly educated portion of their sample, which they
did not expect to be impacted by the program. They estimated the main treatment effects
on the highly educated subsample, and concluded no impact in this group when they did
not obtain statistically significant results. (Hoynes et al., 2016).
We first apply a non-inferiority approach to this analysis. The authors performed 2
placebo tests. We used confidence intervals to examine the effects authors could rule out at
the 5% level, as discussed above.
The first outcome was a metabolic syndrome index, for which the estimated regression
treatment effect was -0.013 (SE = 0.060). The authors could rule out a metabolic index
effect in the placebo group of less than -0.131 or greater than 0.104 at the α = 0.05 level.
The main estimated metabolic index effect in the analytic sample was less than -0.2 for all
specifications. This suggests authors could rule out placebo group effects at least 65% of
the treatment effect. We would need more substance matter knowledge to decide whether
placebo effects of -0.131 or smaller are practically significant.
The second outcome was an economic self-sufficiency index for which the estimated re-
gression treatment effect 0.073 (SE = 0.087). The authors could therefore rule out effects
less than -0.101 or greater than 0.247. The main effect estimates for economic self-sufficiency
ranged from 0.17 to 0.21. They could not say at the 5% level that the placebo effect was
less than the estimated main treatment effect for this outcome.
In our discussion of non-inferiority tests, we noted that power is often a concern. In this
case, the authors had lower power for their placebo test, performed on a subsample of the
data, compared to the main test, which may have affected results.
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We discussed using a lower burden of proof for tests of assumptions as a possible alterna-
tive. If we use a cutoff of α = 0.25, we can reanalyze the placebo test that did not differ from
the main effect. The 75% confidence interval this placebo test is (-0.027 to 0.173), which
rules out most specifications of the main effect.
5.2 Medical cannabis and opioid prescribing
A 2018 paper in JAMA Internal Medicine examined the association between medical
cannabis laws and opioid prescribing by comparing states that made cannabis laws more lib-
eral and those that did not (Bradford et al., 2018). To verify the parallel trends assumption,
they examined whether the slopes were in the same among states that legalized cannabis and
those they did not by testing an interaction between time and whether a state eventually
adopted a cannabis law (excluding post-adoption data). When p > 0.05, they declared that
the assumption held.
The authors performed parallel trends tests for a variety of drugs. For the coefficient on
all opioids, they find a parallel trends coefficient of 2.15 million doses (SE = 5.12), with a
95% confidence interval of (-7.9 to 12.2). This means that they can only rule out an annual
pre-trend difference of -7.9 million doses at the 5% level. The lower bound of -7.9 for the
violation parameter was much greater in magnitude than the total treatment effects they
estimated, a decrease of 2.1 million doses per year in one specification and 3.7 million in the
other. This means they could only rule out an annual pre-trends difference 2-4 times greater
in magnitude than their main effect estimates.
When performing a parallel trends test, authors cannot use post-intervention data. There-
fore the confidence interval for a parallel trends test coefficient is almost always wider than
for main tests.
While we lack data to perform a sensitivity analysis, we could use a regression that allows
for differential trends in the full sample in order to estimate the treatment effect. Similar
approaches have been used in some papers (e.g., Greenstone and Hanna (2014),Roberts et
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al. (2018) in Supplemental Online Content, p. 18).
5.3 Charter school and student performance
A 2016 paper in the American Economic Review compared performance by students
at schools converted into charter schools to a matched sample of students at schools that
were not converted into charter schools. (Abdulkadirolu et al., 2016) As long as the 95%
confidence interval of the difference between schools did exclude overlap 0 in the pre-period,
they considered the parallel trends assumption to hold.
The authors performed parallel trends tests in a few sections in the paper. We reproduce
one of their graphs below (Figure 3, also Figure 2 in the original paper). The authors claimed
that parallel trends hold in all places except for year 0 on the left graph, although in many
places, the 95% confidence intervals in the pre-period appeared visually to outweigh the
effect size in the post-period. As this is also a difference-in-difference analysis, the same
power concerns and potential alternatives also exist here.
Figure 3: Parallel trends figure in Abdulkadiroglu et. al. 2016.
All of these examples illustrate that the statistical evidence to verify important assump-
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tions may be weaker than often stated. As a result, other assessments of robustness may be
appropriate.
6 Conclusion
Other authors have identified the issue of switched hypotheses in tests of modeling as-
sumptions, but did not explore the practicality of equivalence/non-inferiority tests (Hartman
and Hidalgo, n.d.). We discussed how non-inferiority tests may have low power and difficult-
to-set thresholds. For example, our heuristic indicates non-inferiority tests of assumptions
are only powered to rule out violations as big as the treatment effect for which the main
study is powered. In many situations, this power will be unacceptably low because the main
study’s power is low or because the violations of practical significance are much smaller. In
other cases, it may be difficult to set an appropriate threshold for equivalence/non-inferiority
tests.
While conventional tests of model assumptions often use null results as evidence that
assumptions hold, null results alone do not imply “no violation.” In many cases, these tests
have unacceptably high rates of failing to detect important violations. While equivalence/non-
inferiority can address this problem, they often have low power. Assessing model assump-
tions may therefore require other approaches, like more permissive Type I error thresholds for
equivalence/non-inferiority tests or a departure from hypothesis testing in favor of sensitivity
analyses.
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A Search terms Google Scholar results in Table 1
We present the search results used to obtain figures in Table 1 below. Searches were
conducted on May 6, 2018. These are imprecise metrics for several reasons. Some unrelated
articles may be included in results, and some tests required more specific search terms than
others. (For example, we did not search “Komogorov-Smirnov” without “test” because that
term also applies to some theorems. However, we searched “Dickey-Fuller” because to our
knowledge this only commonly applies to the corresponding test.)
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Table 3: Google Scholar search terms for Table 1
Test Google
Scholar
results
(2013-
17)
Google Scholar search term
Kolmogorov-Smirnov test 27,500 “kolmogorov-smirnov test”
Levene, Bartlett,
White/Breusch-Pagan
tests
25,600 “Levene test” OR “Bartlett test” OR “Breusch-Pagan test” OR “Levene’s test” OR
“Bartlett’s test” OR “Breusch-Pagan’s test” OR “White’s test”
Shapiro-Wilk, Anderson-
Darling, Jarque-Bera tests
24,100 Shapiro-Wilk test OR “Anderson-Darling test” OR “Jarque-Bera test” OR “Shapiro-
Wilk’s test” OR “Anderson-Darling’s test” OR “Jarque-Bera’s test”
Proportional hazards test 17,700 “proportional hazards test” OR “proportional hazards assumption” OR “test of pro-
portional hazards” OR “assumption of proportional hazards”
Hosmer-Lemeshow test 17,600 “hosmer lemeshow”
Durbin-Wu-Hausman test 17,300 “Durbin-Wu-Hausman test” OR “Hausman test”
Dickey-Fuller
(DF)/Augmented DF
13,600 “Dickey-Fuller” OR “Augmented Dickey-Fuller”
Sargan-Hansen test 11,900 “Sargan-Hansen test” OR “hansen test” OR “Sargan test”
Placebo test 9,110 “placebo test” OR “placebo tests”
Balance tests 7,390 (“balance test” OR “balance tests” OR “balance table”) AND “experiment”
Parallel trends test 3070 “parallel trends test” OR “parallel trends assumption” OR “test of parallel trends”
OR “assumption of parallel trends”
McCrary test 531 “mccrary test” OR “mccrary tests”
Ramsey Regression Equa-
tion Specification Error Test
(RESET) test
229 “Ramsey Regression Equation Specification Error”
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B Extension of non-inferiority heuristic to other tests
B.1 T-test
To complete the analysis above as a t-test, we substitute Φ for the cumulative distribution
function of the t-distribution with the relevant number of degrees of freedom in section 5.1.
The rest of the math is unchanged.
B.2 Regression coefficients
Consider the linear model:
yi =
p∑
i=1
βixij + i,
where yi is the outcome of interest, each xij is value of the jth covariate for observation
i, and i is the error associated with observation i such that i ∼i.i.d. N(0, σ2). In matrix
form, we write:
X =

x11 x12 . . . x1p
...
...
xn1 xn2 . . . xnp
 , βˆ =

βˆ1
βˆ2
...
βˆp

, y =

y1
y2
...
yn

We examine a Wald test of coefficient i, with the following hypotheses:
H0 : βi < 0
HA : βi ≥ 0
This is a z-test on βˆi. With the normality and homoskedasticity assumptions above, the
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variance of βˆ:
σ2
βˆ
= V ar
((
XTX
)−1
XTy
)
=
(
XTX
)−1
XTV ar(y)X
(
XTX
)−1
= σ2
(
XTX
)−1
Then, σ2
βˆi
= σ2
(
XTX
)−1
ii
, the ith diagonal element of
(
XTX
)−1
. Because the standard
error of βˆi is not dependent on yi, then the calculations in 5.1 hold.
1− β = P
(
βˆi
σβi
> Φ−1
(
1− α
2
))
B.3 Two-sample tests
In a two-sample Z-test, we test the null hypothesis, H0 : θ1 ≤ θ2 against the alternative,
HA : θ1 > θ2. The Z-statistic is:
Z =
X¯1 − X¯2√
σ21
n1
+
σ22
n2
The power calculation can be modified:
1− β = P
 X¯1 − X¯2√
σ21
n1
+
σ22
n2
> Φ(1− α)

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B.4 Other null hypotheses
If the θ0 6= 0, we could have null hypotheses, H0 : θ ≤ θ0 and HA : θ > θ0. This would
lead to a slight modification of our heuristic. We have power 1−β to detect an effect of size
δ = θ − θ0.
1− β = P
(
X¯ − θ0
σ√
n
> Φ−1(1− α)
)
= 1− Φ
(
Φ−1(1− α) + θ − θ0σ√
n
)
1− β = Φ
(
Φ−1(α) +
θ − θ0
σ√
n
)
δ = θ − θ0 =
(
Φ−1(1− β)− Φ−1(α)) √n
σ
Now suppose researchers are concerned that the mean may have changed in a different
group that did not receive the intervention. They want to do a non-inferiority placebo test
on a this group to rule out an effect of size δ. (We assume this group has the same standard
deviation.) In a non-inferiority approach, we assume Xi ∼i.i.d. N(θ, σ2), where θ0 when there
is no violation. Researchers test: H0 : θ ≥ δ,HA : θ < δ. In this case, power to rule out an
effect of size δ is equal to 1− β if θ = 0.
P
(
X¯ − δ
σ√
n
≤ Φ−1(α)
)
= Φ
(
Φ−1(α) +
δ
σ√
n
)
= 1− β
Specifically, we have equal power to rule out the same difference between the true effect
and null hypothesis.
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C Other test conditions
C.1 Two-sided treatment effect test
In a two-sided test, researchers set H0 : θ = 0, HA : θ 6= 0. The power to detect an effect
of size θ0 associated with this test is:
1− β = P
(
X¯
σ√
n
> Φ−1
(
1− α
2
))
+ P
(
X¯
σ√
n
< Φ−1
(α
2
))
= 2P
(
X¯ − θ
σ√
n
< Φ−1
(α
2
)
− θσ√
n
)
= 2Φ
(
Φ−1
(α
2
)
− θσ√
n
)
If we solve for θ∗ that the test has power 1− β to detect, we obtain
θ∗ = σ/
√
N
(
Φ−1
(
1− β
2
)
− Φ−1
(α
2
))
In a one-sided non-inferiority test, researchers would have slightly higher power to rule
out an effect of size θ∗ than the original formulation, equivalent to the increase in power a
one-sided test has compared to a two-sided test (Figure 4).
C.2 Two-sided non-inferiority test
In a non-inferiority approach, we assume Xi ∼i.i.d. N(θ, σ2); if θ = 0, there is no violation..
Researchers typically test: H0 : θ ≥ |θ∗|, HA : θ < |θ∗|. In this case, power to rule out an
effect of size θ∗ is slightly lower (Figure 4). (We assume in these calculations that θ∗ > 0; if
not, then θ∗ would added on the left side of the inequality and subtracted on the right.)
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Power of main effect
test to detect an
effect of size θ *
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Figure 4: Power of different types of tests. The x-axis indicates the effect size measured in
standard deviations. The red line is the power of the original study to detect an effect of size
θ∗ in a two-sided test: H0 : θ = 0, HA : θ 6= 0. The green line is the power of a one-sided test
non-inferiority test to rule out an effect of size θ∗ if in fact θ = 0: H0 : θ ≥ θ∗, HA : θ < θ∗.
The blue line is the power of a two-sided non-inferiority test to rule out an effect of size θ∗
in a two-sided test if in fact θ = 0: H0 : θ ≥ |θ∗|, HA : θ < |θ∗|.
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P(
X¯ − θ∗
σ√
n
< Φ−1
(α
2
)⋂ X¯ + θ∗
σ√
n
> Φ−1
(
1− α
2
) ∣∣∣∣∣θ = 0
)
= P
(
Φ−1
(
1− α
2
)
− θ
∗
σ√
n
≤ X¯σ√
n
≤ Φ−1
(α
2
)
+
θ∗
σ√
n
∣∣∣∣∣θ = 0
)
= Φ
(
Φ−1
(α
2
)
+
θ∗
σ√
n
)
− Φ
(
Φ−1
(
1− α
2
)
− θ
∗
σ√
n
)
= 2Φ
(
Φ−1
(α
2
)
+
θ∗
σ√
n
)
− 1
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